Compare Natera Inc. Common Stock (NTRA) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs PepsiCo, Inc. — how do they compare? Natera Inc. Common Stock trades at $402.15 (market cap $57.03B), while PepsiCo, Inc. trades at $130.76 (market cap $176.16B). The key difference: PepsiCo, Inc. is far larger — about 3.1× Natera Inc. Common Stock's market cap, and PepsiCo, Inc. pays a 4.58% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and PepsiCo, Inc. for 108 Days on average.
| NTRA | PEP | |
|---|---|---|
Market Cap | $57.03B | $176.16B |
Volume | 1,131,157 | 9,536,018 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $170.44 |
52-Week Low | $179.42 | $123.64 |
Typical Hold Time | 0 Days | 108 Days |
Enterprise Value | $56.18B | $216.88B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PepsiCo (PEP) trades at $127.28, up 0.44% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 54.17% gross margins and 52.28% ROE. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts project a $142.38 price target with 67.4% holding neutral positions.
PEP offers stable dividend income and operational cash flow strength, though near-term technical weakness and competitive pricing pressures present risks. The company's valuation at 16.26 P/E appears reasonable given its market leadership, but investors should monitor North American performance trends and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
